Related Experiment Video

Updated: Aug 26, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Gender and ethnic differences in a case-control study of dyslipidemia: using the apolipoprotein A-V gene as an

Shu-Fen Wung1, Bradley E Aouizerat

  • 1College of Nursing, University of Arizona, Tucson 85721-0203, USA. shufen@nursing.arizona.edu

Research and Theory for Nursing Practice
|February 13, 2004
PubMed

Insights

Genetic variations in the apolipoprotein A-V gene influence lipid levels and cardiovascular disease risk. These genetic factors show significant differences across ethnicities and genders, particularly impacting triglyceride levels in Asian women.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Biochemistry

Background:

  • Coronary heart disease (CHD) exhibits population-specific differences and is influenced by gender.
  • Apolipoproteins are key factors in distinguishing individuals with CHD.
  • Apolipoprotein A-V (APOA-V) gene variations are linked to plasma lipids and CHD risk.

Purpose of the Study:

  • To investigate the association between APOA-V gene polymorphisms and lipoprotein profiles.
  • To examine gender and ethnic disparities in the APOA-V T-1131C promoter polymorphism in dyslipidemia patients and controls.

Main Methods:

  • Interdisciplinary genetic research project.
  • Analysis of APOA-V gene promoter polymorphisms (T-1131C).
  • Comparison of genotype frequencies and lipid profiles between ethnic groups and genders.

Main Results:

  • The minor -1131C allele of APOA-V was associated with elevated plasma triglycerides (TG) and various lipoprotein cholesterols.
  • The C allele was significantly more frequent in Asians compared to Europeans.
  • Significant differences in genotype frequency were observed between genders within Asian and European populations, with Asian women carrying the C allele showing a marked increase in TG.

Conclusions:

  • Ethnic-specific and gender-based variations exist in the frequency of the APOA-V -1131C promoter polymorphism.
  • These genetic differences may contribute to disparities in cardiovascular disease development.
  • Understanding these variations can enhance the comprehension of cardiovascular disease etiology.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genetic Variation01:25

Genetic Variation

Genetic variation is the diversity in DNA sequences found among individuals of the same species. This diversity is crucial for a species' survival because it helps organisms adapt to environmental changes. Genetic variation begins with fertilization, where an egg and sperm cell merge. Each of these cells carries 23 chromosomes, up to 46 in the fertilized egg. Chromosomes are long DNA strands that contain genes, the basic units of heredity.
Genes exist in different versions called alleles, which...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...